138 related articles for article (PubMed ID: 23360699)
1. Taxanes as a first-line systemic treatment in metastatic breast cancer.
Urquhart LM
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():15-21. PubMed ID: 23360699
[TBL] [Abstract][Full Text] [Related]
2. Evolution of taxanes in the treatment of metastatic breast cancer.
Binder S
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():9-14. PubMed ID: 23360698
[TBL] [Abstract][Full Text] [Related]
3. Metastatic breast cancer epidemiology and management with a focus on taxanes.
Donovan D
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():5-8. PubMed ID: 23360697
[TBL] [Abstract][Full Text] [Related]
4. Taxanes: impact on breast cancer therapy.
Bachegowda LS; Makower DF; Sparano JA
Anticancer Drugs; 2014 May; 25(5):512-21. PubMed ID: 24552749
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
6. Taxanes in the treatment of early breast cancer.
Ring AE; Ellis PA
Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
[TBL] [Abstract][Full Text] [Related]
7. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
8. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
Herceg D; Vrbanec D
Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
[TBL] [Abstract][Full Text] [Related]
9. Taxanes in elderly breast cancer patients.
Wildiers H; Paridaens R
Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
11. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
Rivera E
Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
[TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Beuselinck B; Wildiers H; Wynendaele W; Dirix L; Kains JP; Paridaens R
Crit Rev Oncol Hematol; 2010 Jul; 75(1):70-7. PubMed ID: 19651523
[TBL] [Abstract][Full Text] [Related]
13. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and docetaxel in the treatment of breast cancer.
Saloustros E; Mavroudis D; Georgoulias V
Expert Opin Pharmacother; 2008 Oct; 9(15):2603-16. PubMed ID: 18803448
[TBL] [Abstract][Full Text] [Related]
15. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
16. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
17. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
18. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
[TBL] [Abstract][Full Text] [Related]
19. Special considerations in the management of older adult patients with metastatic breast cancer.
Donovan D
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():41-8. PubMed ID: 23360702
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
